The MDM2-p53 interaction
- PMID: 14707283
The MDM2-p53 interaction
Abstract
Activation of the p53 protein protects the organism against the propagation of cells that carry damaged DNA with potentially oncogenic mutations. MDM2, a p53-specific E3 ubiquitin ligase, is the principal cellular antagonist of p53, acting to limit the p53 growth-suppressive function in unstressed cells. In unstressed cells, MDM2 constantly monoubiquitinates p53 and thus is the critical step in mediating its degradation by nuclear and cytoplasmic proteasomes. The interaction between p53 and MDM2 is conformation-based and is tightly regulated on multiple levels. Disruption of the p53-MDM2 complex by multiple routes is the pivotal event for p53 activation, leading to p53 induction and its biological response. Because the p53-MDM2 interaction is structurally and biologically well understood, the design of small lipophilic molecules that disrupt or prevent it has become an important target for cancer therapy.
Similar articles
-
A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.Oncogene. 2004 May 20;23(23):4121-9. doi: 10.1038/sj.onc.1207540. Oncogene. 2004. PMID: 15064742
-
Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo.Oncogene. 2001 Aug 16;20(36):4972-83. doi: 10.1038/sj.onc.1204656. Oncogene. 2001. PMID: 11526482
-
Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13125-30. doi: 10.1073/pnas.202480499. Epub 2002 Sep 13. Proc Natl Acad Sci U S A. 2002. PMID: 12232053 Free PMC article.
-
The p53-Mdm2 module and the ubiquitin system.Semin Cancer Biol. 2003 Feb;13(1):49-58. doi: 10.1016/s1044-579x(02)00099-8. Semin Cancer Biol. 2003. PMID: 12507556 Review.
-
Activation and activities of the p53 tumour suppressor protein.Br J Cancer. 2001 Dec 14;85(12):1813-23. doi: 10.1054/bjoc.2001.2128. Br J Cancer. 2001. PMID: 11747320 Free PMC article. Review.
Cited by
-
A natural small molecule harmine inhibits angiogenesis and suppresses tumour growth through activation of p53 in endothelial cells.PLoS One. 2012;7(12):e52162. doi: 10.1371/journal.pone.0052162. Epub 2012 Dec 27. PLoS One. 2012. PMID: 23300602 Free PMC article.
-
Navigating the complexity of p53-DNA binding: implications for cancer therapy.Biophys Rev. 2024 Jul 11;16(4):479-496. doi: 10.1007/s12551-024-01207-4. eCollection 2024 Aug. Biophys Rev. 2024. PMID: 39309126 Free PMC article. Review.
-
Quercetin-induced apoptosis of HT-29 colon cancer cells via inhibition of the Akt-CSN6-Myc signaling axis.Mol Med Rep. 2016 Nov;14(5):4559-4566. doi: 10.3892/mmr.2016.5818. Epub 2016 Oct 10. Mol Med Rep. 2016. PMID: 27748879 Free PMC article.
-
GOF Mutant p53 in Cancers: A Therapeutic Challenge.Cancers (Basel). 2022 Oct 18;14(20):5091. doi: 10.3390/cancers14205091. Cancers (Basel). 2022. PMID: 36291874 Free PMC article. Review.
-
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.J Exp Med. 2016 Sep 19;213(10):2019-37. doi: 10.1084/jem.20160157. Epub 2016 Aug 29. J Exp Med. 2016. PMID: 27573812 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous